ClinicalTrials.gg
RecruitingNCT07085299Updated Jul 25, 2025

Gut Microbiota and Prognostic Outcomes in Intracranial Arterial Stenosis Patients(GROW-ICAS)

An observational study in Intracranial Artery Stenosis, sponsored by Nanjing First Hospital, Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by Nanjing First Hospital, Nanjing Medical University · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Constriction, Pathologic with a site in China — 37 open to participants now, 40 under way, 3 of them phase 3. Constriction, Pathologic · China.

Planned enrollment
7th of 25
500 · median 400
Started
2025
with 8 others
Observational
25 of 81
13 open now
Primary completion
2028-12
later than 33 of 39 live
Registered
66th of 81
by date

Among the 81 studies in Constriction, Pathologic with a site in China, this one is the 7th largest by planned enrollment of the 25 observational ones that give a count, is one of 9 that started in 2025, is one of 25 observational ones, reaches primary completion later than 33 of the 39 other live ones, and was the 66th registered.

Constriction, Pathologic

457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.

Browse Constriction, Pathologic studies →

Open to participants now

37 of the 81 studies in Constriction, Pathologic with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 30 Years to 80 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Constriction, Pathologic with a site in China, or all of them as a file.
02

Study summary

GROW-ICAS (Gut microBiota and prOgnostic Outcomes in IntraCranial Arterial Stenosis) is a prospective observational cohort study that enrolls patients with intracranial arterial stenosis to investigate the correlations between their gut microbiota, metabolomic, and transcriptomic profiles and three key clinical domains: functional outcomes, vascular plaque imaging characteristics, and post-stroke non-motor dysfunctions (including cognitive impairment, depression, anxiety, and fatigue).

03

Conditions studied

  • Intracranial Artery Stenosis

Keywords

  • intracranial artery stenosis
  • Gut Microbiota
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with intracranial arterial stenosis recruited from the Department of Neurology, Nanjing First Hospital (Affiliated Nanjing Hospital of Nanjing Medical University)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 30-80 years.
  2. Intracranial arterial stenosis confirmed by CTA/MRA/DSA.
  3. Local residency ≥6 consecutive months.
  4. Signed .

Exclusion criteria

Exclusion Criteria:

  1. Tandem extracranial stenosis (≥50%) proximal to the target intracranial stenotic vessel.
  2. Non-atherosclerotic intracranial stenosis.
  3. Extracranial/intracranial endovascular treatment within 30 days pre-enrollment or planned intervention within 6 months.
  4. Intracranial hemorrhage within 90 days pre-enrollment.
  5. Pre-existing intracranial tumor, cerebral aneurysm, or arteriovenous malformation.
  6. Cardioembolic embolism.
  7. Active bleeding/hemorrhagic diathesis.
  8. Major surgery within 30 days pre-enrollment or planned within 6 months post-enrollment.
  9. Severe neurological deficits impairing independent living or dementia/psychiatric disorders hindering follow-up.
  10. Pregnancy/lactation/planned pregnancy.
  11. Chronic inflammatory/ diseases.
  12. Uncontrolled hypertension or diabetes.
  13. Severe cardiac/hepatic/renal dysfunction, hematologic disorders, , or \<1 year.
  14. MRI .
  15. History of depression/anxiety/cognitive impairment requiring therapy.
  16. Antibiotic/probiotic// use within 1 month pre-enrollment.
  17. Current/planned participation in other trials.
  18. Inability to cooperate due to psychiatric/emotional disorders.
  19. Other investigator-deemed ineligibility.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Stroke Recurrence in Patients with Symptomatic Intracranial Arterial Stenosis

    Patients with symptomatic intracranial arterial stenosis experiencing recurrent cerebrovascular events, defined as either novel ischemic stroke or transient ischemic attack (TIA).

    Time frame: From enrollment to 1 year

  2. Stroke Occurrence in Patients with Asymptomatic Intracranial Arterial Stenosis

    Incident cerebrovascular events-comprising ischemic stroke or transient ischemic attack (TIA)-occurring in patients exhibiting asymptomatic intracranial arterial stenosis.

    Time frame: From enrollment to 1 year

Secondary outcomes

  1. Changes in Imaging Characteristics of Intracranial Vascular Plaques.

    * Plaque Burden = Σ (Cross-sectional wall area - Cross-sectional lumen area) / Σ Cross-sectional wall area × 100% * Change in Plaque Burden = Plaque burden at Week 24/48 - Baseline plaque burden

    Time frame: From enrollment to 1 year

Other outcomes

  1. Functional outcomes were assessed using the modified Rankin Scale (mRS).

    Functional outcomes were assessed using the modified Rankin Scale (mRS), a 7-point scale ranging from 0 to 6, with higher scores indicating greater disability.

    Time frame: From enrollment to 1 year

  2. Cognitive function was assessed using the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA).

    Both scales have a maximum score of 30 points, with lower scores indicating greater cognitive impairment.

    Time frame: From enrollment to 1 year

  3. Fatigue severity was assessed using the 9-item Fatigue Severity Scale (FSS).

    The FSS is a valid and reliable 7-point Likert scale used for assessing and quantifying fatigue, with scores ranging from 1 (strongly disagree) to 7 (strongly agree). A higher score indicates more severe fatigue.

    Time frame: From enrollment to 1 year

  4. Depression severity was assessed using the 17-item Hamilton Depression Rating Scale (HAMD).

    The HAMD total score serves as a reliable indicator of symptom severity, where lower scores correspond to milder symptoms and higher scores indicate greater symptom severity.

    Time frame: From enrollment to 1 year

  5. Anxiety severity was assessed using the 14-item Hamilton Anxiety Rating Scale (HAMA).

    The Hamilton Anxiety Rating Scale (HAMA-14) was administered to quantify anxiety severity. A direct correlation exists between total scores and clinical symptom burden, with elevated scores denoting increased severity.

    Time frame: From enrollment to 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2028, 42 months after the start.

Of 52 non-industry observational studies under Constriction, Pathologic, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 42 months is above that.

Counting every sponsor, half of 64 studies reached it within 31 months; a quarter within 19 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Jul 25, 2025
StartActual
Jun 1, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07085299
Responsible party
Sponsor
First posted
Jul 25, 2025
Start date
Jun 1, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 25, 2025

Study contacts

Junshan Zhou
Contact
zhjsh333@126.com
8602587726218
Mengmeng Gu
Contact
gumengmeng322@yeah.net
8602587726218

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion